{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_21092", "batch_size": 200, "batch_pos": 89, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 2, "answer": "no", "rationale": "The segment describes stock movement and a potential deal neutrally, lacking high-potency verbs or metaphors.", "method": "llm_batch", "batch_id": "batch_2_6864", "batch_size": 200, "batch_pos": 84, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 3, "answer": "no", "rationale": "The segment describes financial metrics ('climbed 2.4%') which are excluded from Q3.", "method": "llm_batch", "batch_id": "batch_3_13172", "batch_size": 200, "batch_pos": 77, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_15888", "batch_size": 200, "batch_pos": 75, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 5, "answer": "no", "rationale": "The segment reports stock price movement, which is financial news, not public health calming.", "method": "llm_batch", "batch_id": "batch_5_5156", "batch_size": 200, "batch_pos": 75, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser token combined with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_7508", "batch_size": 200, "batch_pos": 62, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_14444", "batch_size": 200, "batch_pos": 59, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 8, "answer": "yes", "rationale": "Describes a potential future action/development capability ('near a deal to fund a late-stage trial') without calming keywords.", "method": "llm_batch", "batch_id": "batch_8_8860", "batch_size": 200, "batch_pos": 22, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
